Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04396886
Other study ID # UW 19-675
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 27, 2020
Est. completion date July 26, 2023

Study information

Verified date May 2024
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).


Description:

All the patients must be registered with the Investigator(s) prior to initiation of treatment. The registration desk will confirm all eligibility criteria and obtain essential information (including patient number). Patients shall receive Bintrafusp alfa treatment through intravenous therapy every two weeks up until disease progression, unacceptable toxicity or for a maximum of 2 years. Survival Follow-up till 2 years will also be performed.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date July 26, 2023
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed non-keratinizing differentiated (World Health Organization WHO Type II) or undifferentiated (WHO Type III) nasopharyngeal carcinoma (NPC) that has recurred at regional or / and distant sites - Measurable disease according to the RECIST criteria (version 1.1) for the evaluation of measurable disease - Received one or more lines of chemotherapy, which must include prior treatment with a platinum agent either for the treatment of metastatic or recurrent disease - Experienced progression of disease within 6 months following completion of a platinum-based combination therapy as part of (neo)-adjuvant therapy - Male or female subjects with age: 18-79 years old - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - No prior immunotherapy - Written informed consent obtained for clinical trial participation and providing archival tumor tissue, if available - Females of childbearing potential or non-sterilized male who are sexually active must use a highly effective method of contraception - Females of childbearing potential must have negative serum or urine pregnancy test - Have life expectancy = 3 months - Adequate organ function as defined as: Absolute neutrophil count = 1.5 x 10^9/L, Platelet count = 100 x 10^9/L, Hemoglobin >= 8.0 g/dL, Serum alanine aminotransferase ([ALT]; serum glutamate-pyruvate transferase [SGPT]), or serum aspartate aminotransferase [AST] where available at the center) < 2.5 x upper limit of normal (ULN), OR < 5 x ULN in the presence of liver metastases - Serum total bilirubin < 2 x ULN - Serum creatinine < 1.5 x ULN Exclusion Criteria: - Prior invasive malignancy within 2 years except for non-invasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, lobular or ductal carcinoma in situ of the breast that has been surgically cured - Isolated local recurrence or persistent disease - Has disease that is suitable for local therapy administrated with curative intent - Severe, active co-morbidity - Currently participating in and receiving clinical trial treatment or has participated in a trial of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment - Has prior chemotherapy, targeted therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (= grade 1 or at baseline) from adverse events due to previous administered agent - Untreated active central nervous system (CNS) metastatic disease, lepto-meningeal disease, or cord compression - Clinically significant (active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (=New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication. - Prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other immuno-regulatory receptors or mechanisms - Irritable bowel syndrome or other serious gastrointestinal chronic conditions associated with diarrhea within the past 3 years prior to the start of treatment - Known history of testing positive for HIV or known acquired immunodeficiency syndrome. - On chronic systemic steroid or any other forms of immunosuppressive medication within 14 days prior to the treatment. Except: Intra-nasal, inhaled, topical steroids, or local steroid injection (e.g., intraarticular injection); Systemic corticosteroids at physiologic doses =10 mg/day of prednisone or equivalent; Steroids as premedication for hypersensitivity reactions due to bintrafusp alfa - Active or prior documented autoimmune or inflammatory disorders in the past 2 years, except diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment - Known active hepatitis B or known hepatitis C is detected; subjects who have been treated and now have an undetectable viral load are eligible - History of primary immunodeficiency or solid organ transplantation - Receipt of live, attenuated vaccine within 28 days prior to the study treatment - Active infection requiring systemic therapy - Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) - Females who are pregnant, lactating, or intend to become pregnant during their participation in the study - Psychiatric disorders and substance (drug/alcohol) abuse

Study Design


Intervention

Drug:
Bintrafusp Alfa
Bintrafusp alfa will be administered intravenously every 2 weeks

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
The University of Hong Kong Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of Objective Tumour Response To evaluate the objective tumor response (ORR) to bintrafusp alfa in previously treated R/M NPC patients per response evaluation criteria of solid tumor (RECIST) version 1.1 From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Progression-Free survival assessment To assess the progression-free survival (PFS) per RECIST version 1.1 From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Time-to-progression (TTP) assessment To assess the time-to-progression (TTP) per RECIST version 1.1 From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Median Survival To assess the median survival From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Toxicity and Tolerability measurement To measure the toxicities and tolerability in previously treated R/M NPC patients receiving bintrafusp alfa with the most updated version of CTCAE criteria From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Objective Response Rate (ORR) To evaluate ORR, PFS and TTP per immune-related RECIST (irRECIST) From the date of screening to radiographically documented progression according to irRECIST, assessed up to 2 years
Secondary Survival rate assessment To measure the survival rate in 12 months and 24 months From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Duration of Response (DOR) evaluation To evaluate the duration of response (DOR) in previously treated R/M NPC patients receiving bintrafusp alfa From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Investigate the relationship between the response to bintrafusp alfa and plasma Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) level EBV-DNA will be determined using real-time quantitative polymerase chain reaction and the clearance (half-life) during the first 4 weeks of bintrafusp alfa will be measured. The half-life will be correlated with patients ORR, PFS, and OS From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Disease Control Rate (DCR) Defined as the percentage of patients with a CR, PR, or SD = 6 months per RECIST 1.1 From the date of screening to radiographically documented progression according to RECIST 1.1, assessed up to 2 years
Secondary Time to Response (TTR) Defined as the duration to first documented tumor response From the date of screening to first radiographically documented tumor response according to RECIST 1.1, assessed up to 2 years
Secondary Quality of Life (QoL) To evaluate via the patient-reported EORTC-QLQ-C30 and H&N-35 questionnaires Every 12 weeks from the date of screening in the first year of study enrolment
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT05981170 - Rurality Adapted Physical Activity Sport Health
Not yet recruiting NCT03058809 - Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A